Grade 2 Hand-foot Syndrom
Conditions
Keywords
Hand Foot Syndrome Grade 2, Common Terminology Criteria for Adverse Events (CTCAE), Oncology, Repair Cream, Cutaneous events, Palmar-plantar erythrodysesthesia syndrome, Targeted Therapies or Conventional Chemotherapy
Brief summary
The aim of the study is to assess the restorative efficacy of the cosmetic product Onco-Repair vs placebo of the most affected palmer face in subject with grade 2 HFS induced by targeted therapies or conventional chemotherapy.
Detailed description
HFS, also known as Palmar-Plantar Erythrodysethesia, is a common adverse event observed in subjects under anti-tumor therapy with conventional chemotherapy or targeted thérapies. The initial symptoms are dysesthesia and tingling in the palms, fingers and soles of feet and erythema, which may progress to burning pain with dryness, cracking, desquamation, ulceration and oedema. Sensory impairment, paresthesia and pruritus have also been reported. Palms of the hands are more frequently affected than soles of the feet, and might even be the only area affected in some subjects. Although HFS is rarely life-threatening, the skin changes are often painful and debilitating and can impair with the general activities of daily living and quality of life. No standard prevention for HFS has not been established yet. Onco-Repair is a nourishing and repairing cream specially formulated to treat grade 2 HFS which demonstrate skin tolerance, hypoallergenicity and efficacy through several preclinical and clinical studies on healthy subjects. Therefore, a randomized, double-blind, placebo-controlled study will be conducted to evaluate efficacy and safety of topical cream 'Onco-Repair' on HFS.
Interventions
OTHEROnco-Repair/ Placebo
Cream must be applied twice a day, in the morning and evening, on the hands and feet (palmo-plantar areas and interdigital spaces included) previously cleaned with Atoderm Intensive Foaming Gel, chosen as a standardized hygiene product.
Sponsors
NAOS Institute of Life Science
Quanta Medical
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Masking description
Cosmetic product Onco-Repair and placebo will be filled in the tubes with same appearance and smell. The tubes will be marked anonymusioly
Intervention model description
Phase III multicenter, double blind, superiority, prospective, randomised controlled study Subjects will be randomized to receive either cosmetic product Onco-Repair or placebo in a 1:1 ratio
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Who suffers from grade 2 HFS * Subject under anti-tumor treatment known to cause this toxicity: targeted therapies or conventional chemotherapy: 5-Fluorouracile, Aflibercept, Axitinib, Bévacizumab, Capécitabine, Cediranib, Cytarabine, Dabrafenib, Docétaxel, Doxorubicine, Epirubicine, Pazopanib, Sorafenib, Sunitinib, Trastuzumab, Regorafenib, Vemurafenib and any other anti-tumor treatment that may lead to this toxicity * Subject 18 years old and more * Subject having been informed, having signed a free, informed and written consent * Woman of childbearing age using contraception deemed effective Non-Inclusion Criteria: * Pregnant or lactating women * Subject having a history of allergic contact dermatitis or irritation to any of the components of the investigational products * Subjects with another skin pathology that may interfere with the evaluation of a HFS (at the investigator's discretion) * Subject under anti-inflammatory treatment * Subject participating in another clinical study during the duration of the study, except in a study assessing one of the molecules listed in the section above * Subject who has already been treated for Grade 2 HFS or under other local treatment or cosmetic product * Subject refusing to interrupt the application of his/her usual care * Subject having a strongly altered general condition and / or non-autonomous subject (Karnofsky index \<50%) * Subject in linguistic or psychic impossibility to understand and sign informed consent or in the impossibility of submitting to the medical follow-up of the study * Subject deprived of liberty by administrative or judicial decision, or under guardianship
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall success | 28 days | A subject is considered to have attained success if he achieves at least one grade improvement in HFS for the most affected palmer face according to the National Cancer Institute CTCATE V5.0 at any time during study period (28 days). The subjects will be defined in success or failure according to the following rules: Success: switch from grade 2 to grade 1 or grade 0 Failure: switch from grade 2 to grade 3 If subjects remain at grade 2 at the end of the study, they will be classified as either success or failure according to the evolution of clinical signs and / or quality of life assessed using the Dermatological Life Quality Index (DLQI) scale from D0 to D28. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Clinical parameters such as lesion color | Day 0 (inclusion) , Day 7 and Day 28 | Clinical parameters such as lesion color will be assessed * On e-CRF at D0, D7 and D28 * from D0 to D28 using a standardized diary completed by subjects |
| Clinical parameters such as presence of blisters | Day 0 (inclusion) , Day 7 and Day 28 | Clinical parameters such as presence of blisters will be assessed * On e-CRF at D0, D7 and D28 * from D0 to D28 using a standardized diary completed by subjects |
| Clinical parameters such as fissures/cracks | Day 0 (inclusion) , Day 7 and Day 28 | Clinical parameters such as fissures/cracks will be assessed * On e-CRF at D0, D7 and D28 * from D0 to D28 using a standardized diary completed by subjects |
| Assessment of quality of life from D0 to D28 using Dermatology Life Quality Index scale | 28 days | Quality of life will be assessed from D0 to D28 using Dermatology Life Quality Index scale. It is a simple 10-question validated questionnaire that has been used in over 40 different skin conditions in over 80 countries and is available in over 90 languages. Meaning of Dermatology Life Quality Index scale Scores: 0 to 1 = no effect at all on patient's life 2 to 5 = small effect on patient's life 6 to 10 = moderate effect on patient's life 11 to 20 = very large effect on patient's life 21 to 30 = extremely large effect on patient's life |
| Assessment of symptoms | Day 0 (inclusion) , Day 7 and Day 28 | Such as intensity of lesions, feeling of subjects, etc will be assessed: on e-CRF at D0, D7 and D28, from D0 to D28 using a standardized diary completed by subjects |
| Assessment of pain score and prurit at D0, D7 and D28 using a 100 Visual Analogue Scale [Visual analogue scale, 0 (no pain, no prurit) and 100 (worst possible pain or prurit)] | Day 0 (inclusion) , Day 7 and Day 28 | Pain score and prurit will be assessed at D0, D7 and D28 using a 100 Visual Analogue Scale \[Visual analogue scale , 0 (no pain, no prurit) and 100 (worst possible pain or prurit)\] |
| Time to onset of grade 1 or 0 will be assessed using time (in days) from study commencement (inclusion, D0) to first occurrence of grade 1 or lower HFS according to the CTCAEV5.0 | 28 days | Time to onset of grade 1 or 0 will be assessed using time (in days) from study |
| Cosmetic parameters such as nourishing power of the cream will be assessed at D28 using a standardized diary | 28 days | Nourishing power will be assessed at D28 using a standardized diary completed by subjects. |
| Cosmetic parameters such as soothing power of the cream will be assessed at D28 using a standardized diary | 28 days | Soothing power will be assessed at D28 using a standardized diary completed by subjects. |
| Cosmetic parameters such as penetration power of the cream will be assessed at D28 using a standardized diary | 28 days | Penetration power will be assessed at D28 using a standardized diary completed by subjects. |
| Assessment of compliance | 28 days | The compliance will be assessed at the end of the study: subject will be considered to be compliant if he/she applied at least the theoretical consumption of 60% of the product. |
| The overall tolerance will be assessed by the investigator (Subject interrogation). This evaluation will be carried out during visits using the following rating: 1 = Very good tolerance 2 = Good tolerance 3 = Middle tolerance 4 = Poor tolerance | 28 days | 1. = Very good tolerance: no functional signs of discomfort and no objective signs during examination 2. = Good tolerance: some functional signs of minimal and transient discomfort that did not interrupt the applications and no objective signs during examination 3. = Middle tolerance: functional signs of discomfort, net or persistent, or objective signs during examination that did not interrupt the applications of the investigationalproduct 4. = Poor tolerance: functional and / or objectives signs leading to discontinuation of the use of the investigational product |
| Safety will be will be evaluated in terms of: - the number of subjects presenting during the study period at least : One AE/ One SAE - the total number of AEs during the study period - the total number of SAEs during the study period | 28 days | Safety will be assessed on the basis of adverse event (AE) reports |
| Assessment of the repair quality of skin | Day 0 (inclusion) , Day 7 and Day 28 | The repair quality of skin will be assessed from D0, D7 and D28 using a standardized diary completed by subjects. |
Countries
France
Outcome results
None listed